Previous 10 | Next 10 |
AdaptHealth (NASDAQ: AHCO ) initiated with Buy rating and $17 (31% upside) price target at Stifel. More news on: AdaptHealth Corp., DURECT Corporation, InMed Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more ...
The following slide deck was published by United Therapeutics Corporation in conjunction with this Read more ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Jan. 6, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt , Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the...
BeyondSpring (NASDAQ: BYSI ) initiated with Market Perform rating at Oppenheimer. More news on: BeyondSpring Inc., Centogene N.V., Curaleaf Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
The MannKind ( MNKD ) saga continues to unfold as it travels a desolate highway to a future that is becoming bleaker for those opting to own their common stock. Within the next two months, we will have seen Afrezza being FDA approved during seven (7) calendar years. As for being actively marke...
MannKind ( MNKD ) reported its Q3 earnings last week, and for the most part the company metrics were in line with the projections I have outlined. The company reported revenue of $14.6 million, which included $5.7 million in Afrezza net revenue from the United States and $700,000 in Afrezza ne...
United Therapeutics ( UTHR ) reported its Q3 2019 earnings on October 30, 2019. The company reported a profit of $163 million or $3.83 per share. Revenues were an impressive $402 million with net income of $132 million. While the year-over-year comparisons were slightly down, the numbers del...
Image source: The Motley Fool. United Therapeutics Corp (NASDAQ: UTHR) Q3 2019 Earnings Call Oct 30, 2019 , 9:00 a.m. ET Operator Continue reading
United Therapeutics Corporation (UTHR) Q3 2019 Earnings Conference Call October 30, 2019 09:00 A.M. ET Company Participants James C. Edgemond - CFO & Treasurer Dr. Martine A. Rothblatt - Chairman and CEO Michael I. Benkowitz - President and COO Conference Call Participants...
2019 hasn't been a great year so far for United Therapeutics (NASDAQ: UTHR) . The pharmaceutical stock was down 20% heading into the company's third-quarter update. But United Therapeutics announced its third-quarter results before the market opened on Wednesday, spurring a nice ju...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...